Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

被引：0
|
作者：
Ghanima, Waleed [1 ,2 ,3 ]
McDonald, Vickie [4 ]
Jain, Shivi [5 ]
Carpenedo, Monica [6 ]
Oliva, Esther N. [7 ]
Hultberg, Anna [8 ]
Gandini, Domenica [8 ]
Hofman, Erik [8 ]
Van Bragt, Tonke [8 ]
Parys, Wim [8 ]
van Hoorick, Benjamin [8 ]
Miyakawa, Yoshitaka [9 ]
Broome, Catherine M. [10 ]
机构：
[1] Kalnes, Ostfold Hosp Trust, Dept Med Hematol Oncol & Res, Gralum, Norway
[2] Oslo Univ Hosp, Dept Hematol, Oslo, Norway
[3] Univ Oslo, Inst Clin Med, Oslo, Norway
[4] Barts Hlth NHS Trust, London, England
[5] Rush Univ, Med Ctr, Div Hematol Oncol Cell Therapy, Chicago, IL USA
[6] ASST Osped San Gerardo Monza, Monza, Italy
[7] Grande Osped Metropolitano, Haematol Unit, Reggio Di Calabria, Italy
[8] Argenx, Ghent, Belgium
[9] Saitama Med Univ Hosp, Saitama, Japan
[10] Georgetown Univ, Washington, DC USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153261
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3165
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Pharmacokinetic/Pharmacodynamic Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia
    Wittlin, Beatriz
    McDonald, Vickie
    Ghanima, Waleed
    Broome, Catherine
    Hultberg, Anna
    Gandini, Domenica
    Parys, Wim
    Hofman, Erik
    Miyakawa, Yoshitaka
    Jain, Shivi
    Carpenedo, Monica
    Oliva, Esther
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 44 - 44
  • [2] PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) SIMULATIONS GUIDE SELECTION OF THE DOSE FOR ADMINISTRATION OF EFGARTIGIMOD PH20 SUBCUTANEOUSLY IN A PHASE 3 CLINICAL TRIAL IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
    Ghanima, W.
    McDonald, V.
    Jain, S.
    Carpenedo, M.
    Oliva, E. N.
    Hultberg, A.
    Gandini, D.
    Hofman, E.
    Van Bragt, T.
    Parys, W.
    van Hoorick, B.
    Godar, M.
    Rocca, F.
    Miyakawa, Y.
    Broome, C. M.
    [J]. HAEMATOLOGICA, 2022, 107 : 94 - 94
  • [3] Pharmacokinetic/pharmacodynamic (PK/PD) modeling and dose regimen simulations to guide dose selection in phase 2a of an antisense oligonucleotide, targeting human apoB, in hypercholesterolemic subjects
    Yu, Rosie Z.
    Geary, Richard S.
    Bradley, JoAnn
    Chuang, Emil
    Wedel, Mark
    Fuhr, Rainard
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1068 - 1068
  • [4] Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma
    Ly, Neang
    Zheng, Yanan
    Griffiths, Janet M.
    Merwe, Rene
    Agoram, Balaji
    Parnes, Jane R.
    Roskos, Lorin
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (07): : 901 - 912
  • [5] Pharmacokinetic/pharmacodynamic (PK/PD) modeling and trial simulations to guide dose selection with CNTO 328, a chimeric anti-IL-6 monoclonal antibody (MAb), in patients with renal cell carcinoma (RCC).
    Jang, H
    Prabhakar, U
    Jiao, Q
    Ford, J
    Miller, BE
    Davis, HM
    Graham, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 189S - 189S
  • [6] Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress
    Newland, Adrian C.
    Liebman, Howard A.
    McDonald, Vickie
    Michel, Marc
    Miyakawa, Yoshitaka
    Parys, Wim
    De Haard, Hans
    Ulrichts, Peter
    Godar, Marie
    De Beuf, Kristof
    Ayguasanosa, Jaume
    Broome, Catherine M.
    Kuter, David J.
    [J]. BLOOD, 2020, 136
  • [7] Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling and Trial Simulation for Selection of Optimal Dose of Fedratinib (SAR302503)
    Liu, Li
    Xu, Christine
    Su, Yaming
    Ma, Lei
    Quan, Hui
    Kanamaluru, Vanaja
    Shun, Zhenming
    Deutsch, Paul
    Zaks, Tal
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S18 - S18
  • [8] Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1
    Zhang, Steven
    Amrite, Aniruddha
    Tan, Beesan
    Jamsen, Kris
    Pradhan, Sudeep
    Choy, Steve
    Plotkin, Horacio
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [9] Impact of population pharmacokinetic (PK) modeling, logistic regression and PK/pharmacodynamic (PD) simulation of solabeoron to aid in the dose selection of a phase IIB study in patients with irritable dowel syndrome (IBS).
    Cox, Donna S.
    Boyle, Duane A.
    Foss, Michael J.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1101 - 1101
  • [10] Optimizing the Gantenerumab Phase 3 Dosing Regimen Through PK/PD Modeling and Clinical Trial Simulations
    Hofmann, Carsten
    Gieschke, Ronald
    Retout, Sylvie
    Milosavljevic-Ristic, Smiljana
    Voyle, Nicola
    Delmar, Paul
    Serafin, Daniel
    [J]. NEUROLOGY, 2018, 90
12345